1. Late thrombosis with drug-eluting stents: Anatomy of a controversy and lessons learned

   • Steven E. Nissen

   Editor’s Commentary Pages: 429 - 431

2. Web Alert

   Announcement Pages: 432 - 433

3. Treating high blood pressure in patients with stable coronary artery disease: How low should we go?

   Hypertension Pages: 437 - 440

4. β-blockers: No longer an option for uncomplicated hypertension

   • Sripal Bangalore
   • Gayathri Kamalakkannan
   • Franz H. Messerli

   Hypertension Pages: 441 - 446

5. Primary aldosteronism

   • Richard J. Auchus
   • Fiemu E. Nwariaku

   Hypertension Pages: 447 - 452

6. Renovascular hypertension in 2007: Where are we now?

   • Stephen C. Textor

   Hypertension Pages: 453 - 461

7. Arterial stiffness: Is it ready for prime time?

   • Stanley S. Franklin

   Hypertension Pages: 462 - 469

8. Aliskiren: The first direct renin inhibitor for hypertension

   • Anton H. van den Meiracker
   • A. H. Jan Danser

   Hypertension Pages: 470 - 476

9. Cardiovascular risk in the metabolic syndrome: Fact or fiction?

   • Peter M. Nilsson

   Lipid Abnormalities and Cardiovascular Prevention Pages: 479 - 485

10. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease

    • H. Bryan Brewer

    Lipid Abnormalities and Cardiovascular Prevention Pages: 486 - 492

11. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease

    • Philip J. Barter
    • Rajesh Puranik
    • Kerry-Anne Rye

    Lipid Abnormalities and Cardiovascular Prevention Pages: 493 - 498

12. Residual risk in statin-treated patients: Future therapeutic options

    • Catherine Y. Campbell
    • Juan J. Rivera
    • Roger S. Blumenthal

    Lipid Abnormalities and Cardiovascular Prevention Pages: 499 - 505